Szisztémás szklerózis (szkleroderma): vizsgálatok itt: Japán
5 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleRollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
- Where
- Fukuoka, Kanazawa, Maebashi, Nagoya, Sapporo, Yokohama
- Életkor
- 5 év to 80 év
- People
- 1072 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07691970 - 3. fázisTaking peopleA Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Where
- Aichi, Nagoya, Aichi, Toyoake, Fukuoka, Kitakyushu, Gifu, Gifu, Hiroshima, Hiroshima, Hokkaido, Sapporo, Ishikawa, Kanazawa, Kagawa, Kita-gun, Kanagawa, Kawasaki, Kanagawa, Sagamihara, Kanagawa, Yokohama, Kyoto, Kyoto, Miyagi, Sendai, Nagasaki, Nagasaki, Osaka, Takatsuki, Saitama, Iruma-gun, Tokyo, Bunkyo-ku, Tokyo, Shinjuku-ku, Toyama, Toyama
- Életkor
- 18 év and over
- People
- 448 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07497087 · EU 2025-523884-39-00 - 3. fázisNot yet taking people in JapánA Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
- Where
- Bunkyo-ku, Fukuoka, Maebashi, Okayama, Sapporo, Suita, Yokohama
- Életkor
- 16 év and over
- People
- 92 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07335562 · EU 2025-524337-11-00 - 3. fázisTaking peopleA Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- Where
- Aichi, Gunma, Hiroshima, Hokkaido, Tokushima, Tokyo, Yamanashi
- Életkor
- 18 év and over
- People
- 514 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06716606 - 2/3. fázisTaking peopleA Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- Where
- Gunma, Hiroshima, Hokkaido, Kanagawa, Miyagi, Shizuoka, Tokushima, Tokyo
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT05878717 · EU 2023-503219-14-01